FDA approves Moderna’s first seasonal mRNA flu vaccine — full approval for 50–64, accelerated OK for 65+
FDA approved Moderna’s mRNA-1010 seasonal flu vaccine (mFLUSIVA), giving full approval for ages 50–64 and accelerated approval for 65+, pending a confirmatory study.